These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antitumour alkylating agents: cytotoxic action and organ toxicity. Connors TA IARC Sci Publ; 1986; (78):143-5. PubMed ID: 3583387 [No Abstract] [Full Text] [Related]
23. [Effect of bone marrow homotransplantation on the toxicity and antineoplastic property of some alkylating agents]. Veksler IG; Shevchenko VN Vopr Onkol; 1965; 11(7):71-6. PubMed ID: 4956684 [No Abstract] [Full Text] [Related]
24. Some pyrimidines of biological and medicinal interest. 3. Cheng CC; Roth B Prog Med Chem; 1971; 8(1):61-117. PubMed ID: 4935664 [No Abstract] [Full Text] [Related]
30. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Frei E; Holden SA; Gonin R; Waxman DJ; Teicher BA Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570 [TBL] [Abstract][Full Text] [Related]
31. Modulation of antitumor alkylating agents (AA). Teicher BA; Frei E Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721 [No Abstract] [Full Text] [Related]
32. Conference on a new look at older drugs in cancer treatment: Project to Review Older Drugs (PROD). Sponsored by the Division of Cancer Treatment, National Cancer Institute, June 8-9, 1982, at the National Institutes of Health, Bethesda, Maryland. Med Pediatr Oncol; 1983; 11(6):383A-528B. PubMed ID: 6669143 [No Abstract] [Full Text] [Related]
33. Antineoplastic agents and the liver. Ménard DB; Gisselbrecht C; Marty M; Reyes F; Dhumeaux D Gastroenterology; 1980 Jan; 78(1):142-64. PubMed ID: 7350020 [No Abstract] [Full Text] [Related]
34. Selection of carriers for alkylating moieties to increase their antitumor specificity: a different aspect. Niculescu-Duvăz I; Baracu I Cancer Treat Rep; 1977 Aug; 61(5):929-31. PubMed ID: 890700 [No Abstract] [Full Text] [Related]
35. [Tumour chemotherapy. Syntheses of N-acetyl-N-(3-[bis-(beta-chloroethyl)-amino]-6-methyl-phenyl)-glycine and its demethyl analogues]. Sun HL; Shen SY; Shu HL; Owen TY Yao Xue Xue Bao; 1965 Aug; 12(8):500-6. PubMed ID: 5899133 [No Abstract] [Full Text] [Related]
36. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813 [TBL] [Abstract][Full Text] [Related]
37. Anticancer active illudins: recent developments of a potent alkylating compound class. Schobert R; Knauer S; Seibt S; Biersack B Curr Med Chem; 2011; 18(6):790-807. PubMed ID: 21182482 [TBL] [Abstract][Full Text] [Related]
38. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968 [TBL] [Abstract][Full Text] [Related]
40. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. Denny WA; Wilson WR J Med Chem; 1986 Jun; 29(6):879-87. PubMed ID: 3712377 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]